Sexuality in Adult Patients With Congenital Heart Disease and Their Partners

Winter, Michiel M.; Reisma, Claire; Kedde, Harald; Bouma, Berto J.; Vis, Jeroen C.; Luijendijk, Paul; Witte, Piet de; Zwinderman, A.H.; Vliegen, Hubert W.; Pieper, Petronella G.; Dijk, Arie P.J. van; Mulder, Barbara J.M.

doi:10.1016/j.amjcard.2010.06.027

Cited by 21 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Menstrual discomfort occurred in 29% to 49% of survey respondents; cardiac symptoms with sexual activity occurred in 6% to 26% of women. Winter et al 230 reported a survey of 133 Dutch patients with CHD and 74 partners; the study found that compared with the general Dutch population, patients were less likely to be in a relationship. Both patients and their partners reported a higher level of relational satisfaction than the general population.…”

Section: Sexual Dysfunction In Older Adults With Chdmentioning

confidence: 99%

Congenital Heart Disease in the Older Adult

Bhatt¹,

Foster²,

Kuehl³

et al. 2015

Circulation

203

View full text Add to dashboard Cite

Section: Sexual Dysfunction In Older Adults With Chdmentioning

confidence: 99%

Congenital Heart Disease in the Older Adult

Bhatt¹,

Foster²,

Kuehl³

et al. 2015

Circulation

203

View full text Add to dashboard Cite

“…Long-term survival is excellent. 1 Most patients lead normal lives [2][3][4] and remain asymptomatic until adulthood. 5 However, in adult life, late sequelae occur frequently and include progressive right ventricular dilatation and dysfunction, [6][7][8][9] impaired exercise tolerance, 5,10,11 and arrhythmias and premature death.…”

mentioning

confidence: 99%

Effect of Valsartan on Systemic Right Ventricular Function

et al. 2013

Self Cite

View full text Add to dashboard Cite

Editorial see p 314 Clinical Perspective on p 330In both asymptomatic and symptomatic patients with systemic left ventricular dysfunction, inhibition of the reninangiotensin aldosterone system (RAAS) decreases both Background-The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. Methods and Results-We conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindication for magnetic resonance imaging, multirow detector computed tomography. Secondary end points were change in right ventricular volumes and mass, V · o 2 peak, and quality of life. Primary analyses were performed on an intention-to-treat basis. A total of 88 patients (valsartan, n=44; placebo, n=44) were enrolled in the trial. No serious adverse effects occurred in either group. There was no significant effect of 3-year valsartan therapy on systemic right ventricular ejection fraction (treatment effect, 1.3%; 95% confidence interval, −1.3% to 3.9%; P=0.34), maximum exercise capacity, or quality of life. There was a larger increase in right ventricular end-diastolic volume (15 mL; 95% confidence interval, 3-28 mL; P<0.01) and mass (8 g; 95% confidence interval, 2-14 g; P=0.01) in the placebo group than in the valsartan group. Conclusions-There was no significant treatment effect of valsartan on right ventricular ejection fraction, exercise capacity, or quality of life. Valsartan was associated with a similar frequency of significant clinical events as placebo. Small but significant differences between valsartan and placebo were present for change in right ventricular volumes and mass. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN52352170. 17,20,21 In asymptomatic patients, on the other hand, there was no effect on ventricular function, and the effect on ventricular remodeling was much less pronounced. [22][23][24] In patients with a systemic right ventricle, the role of pharmacological RAAS blockade has not been established. Because angiotensin II receptor density is similar in both the left and right ventricles, and neurohormonal activity is similar to that observed in patients with stable heart failure, one would expect a similar effect.25-27 However, in 2 small placebo-controlled trials (n=17 and n=29, respectively), RAAS inhibition had no beneficial effect on exercise capacity, right ventricular function, or remodeling. 28,29 These studies, on the other hand, had only short-term follow-up and low patient numbers. Moreover, predominantly asymptomatic patients were included. Results from retrospective and single-arm studies have been eq...

show abstract

“…Recent studies have described an increased prevalence of erectile dysfunction, 30 decreased sexual esteem, and/or distress with sex in adults with CHD. 31 Therefore, it is important for fellows to understand the complex relationship between cardiovascular disease, erectile dysfunction, and endothelial dysfunction. 32 Endothelial dysfunction is not only an important process in the development of atherosclerotic cardiovascular disease, but also plays a role in the pathophysiologic mechanisms that contribute to erectile dysfunction.…”

Section: Assessment Of Sexual Functionmentioning

confidence: 99%